IMINOCHAP | Linksium
Back to portfolio

IMINOCHAP

Maturation

Pharmacological chaperone therapy to treat patients with Pompe disease

profilePhoto   Valentine Panel
Linksium Contact Valentine Panel +33 (0)6 35 81 73 67 valentine.panel@linksium.fr
190011 IMINOCHAP image

Benefits

  • 1st oral treatment
  • Increased bioavailability/efficiency
  • Patient quality of life
  • Reduction of the cost of treatment

Key words

  • Pompe disease
  • Rare disease
  • Pharmacological chaperones
  • Small molecules

Intellectual Property

  • 1 patent

Laboratory

  • DCM

Institutions

  • CNRS
  • UGA

Linksium Continuum

  • Maturation

Context

Pompe disease is a rare genetic disorder, requiring lifetime treatment with IV enzyme replacement therapy (ERT). It is caused by a defect or mutation in the lysosomal enzyme acid α-glucosidase (GAA) resulting in severe heart and skeletal muscle myopathies.

Technology

We have identified a new class of small molecules with the ability to specifically and selectively bind to GAA in order to stabilize the enzyme in its optimal conformation and enhance its activity in lysosomes.

Advantages

Pharmacological chaperone therapy (PCT) would combine the advantages of oral administration of small molecules, better distribution in tissues (including the central nervous system), and less cumbersome treatment associated with lower cost compared to ERT.

State of progress

GAA specific and selective chaperone activity has been demonstrated in vitro and ex vivo on patient fibroblasts, the next step is the validation of POC in vivo on mice.

Applications

Oral treatment of Pompe disease would save lives in cases where ERT is ineffective. In addition, in combination with ERT, it would allow for the reduction of high doses of the enzyme administered and the spacing of perfusions to reduce side effects and improve patients' quality of life.

Featured articles

Nora Dempsey and deeptech innovations

1, 2 and 3 startups for Nora Dempsey, National Medal of Innovation 2021

Nora Dempsey is one of the four winners of National Medal for Innovation 2021 awarded by CNRS. Nora Dempsey, born in Ireland, has gained an international recognition for her research in Grenoble on...

Read the article
Dd amiral 2018 Frenchweb

Amiral Technologies, la startup IA grenobloise spécialisée dans les solutions de maintenance prédictive, intègre Station F

An ambitious promise: to invent a zero-defect and zero-downtime future for industry. Amiral Technologies, a startup co-founded and boosted by Linksium, based on the technological prowess of the Gre...

Read the article